Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
![]() |
- FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting.
- The designation recognizes the program's potential to address an important unmet need by enabling an imaging-first approach to initial prostate cancer diagnosis.
- Fast Track facilitates...
Read more: Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging





